Is AMGN or BMY more undervalued in 2026?

CirclFi compares Amgen Inc. (AMGN) and Bristol-Myers Squibb Company (BMY) using 13 institutional-grade valuation models. AMGN has a Quality of Company score of 9.0/10 while BMY scores 10.0/10.

Which is a better buy — AMGN or BMY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AMGN and BMY valuations compare?

AMGN at $336.48 and BMY at $56.91 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AMGN vs BMY Valuation Comparison 2026 — Intrinsic Value Analysis

AMGN

Drug Manufacturers - General

Amgen Inc.

Quality

9.0

out of 10

Value Trap

SAFE

Price

$336.48

Last close

Models

12/13

Active

BMY

Drug Manufacturers - General

Bristol-Myers Squibb Company

Quality

10.0

out of 10

Value Trap

SAFE

Price

$56.91

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	AMGN Fair Value	AMGN Upside	BMY Fair Value	BMY Upside
Bayesian DCF	Intrinsic	$109.14	-67.6%	$123.15	+116.4%
Earnings Power Value	Intrinsic	$222.76	-33.8%	$52.56	-7.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AMGN vs BMY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AMGN vs BMY — Which Stock Is More Undervalued?

BMY scores higher with a 10.0/10 quality rating vs AMGN's 9.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Amgen Inc. (AMGN) and Bristol-Myers Squibb Company (BMY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AMGN currently trades at $336.48 with a QOC of 9.0/10, while BMY trades at $56.91 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).